摘要
背景:前列腺癌是一种在男性生殖系统中的腺体前列腺中的异常细胞生长的疾病。虽然老年人和家族病史被认为是前列腺癌的危险因素,但这种癌症的病因仍不清楚。目前,前列腺癌是所有人种男性癌症死亡的主要原因之一。 方法:在这篇综述中,我们首先探讨病毒感染对前列腺癌的影响,随后总结在过去的几年里溶瘤病毒治疗前列腺癌的发展。 结果:越来越多的证据表明,各种病毒感染是可能导致前列腺癌的发病机制。现有的研究提供了强有力的证据,至少有两个病毒(RXMV,HPV)将可以导致前列腺变为肿瘤,而且会影响恶性前列腺癌患者生活质量。传统的治疗方法包括化疗和放疗不能区分癌细胞和正常细胞,这是一个严重的缺点,将会增加前列腺癌患者在治疗过程中的毒性反应。到目前为止,很少有其他方法可用于治疗晚期前列腺癌患者。溶瘤病毒可以通过病毒复制和细胞毒性蛋白的表达对基因改造诱导癌细胞裂解。 结论:病毒治疗正在发展成为癌症的新疗法,它采用亲瘤的和溶瘤的病毒通过自己的能力找到并破坏体内肿瘤细胞。溶瘤病毒是一种相对较新的抗肿瘤免疫治疗药物,对溶瘤病毒使用治疗前列腺癌的道路仍然有一些障碍。
关键词: 前列腺癌,病毒,基因突变,病毒治疗,溶瘤病毒,亲瘤病毒。
图形摘要
Current Cancer Drug Targets
Title:Virus, Oncolytic Virus and Human Prostate Cancer
Volume: 17 Issue: 6
关键词: 前列腺癌,病毒,基因突变,病毒治疗,溶瘤病毒,亲瘤病毒。
摘要: Background: Prostate cancer (PCa), a disease, is characterized by abnormal cell growth in the prostate - a gland in the male reproductive system. Although older age and a family history of the disease have been recognized as the risk factors of PCa, the cause of this cancer remains unclear. Currently, PCa is one of the leading causes of cancer death among men of all races.
Method: In this review study, we first discuss the controversy of the contribution of virus infection to PCa, and subsequently summarize the development of oncolytic virotherapy for PCa in the past several years. Results: Mounting evidence suggests that infections with various viruses are causally linked to PCa pathogenesis. Published studies have provided strong evidence that at least two viruses (RXMV and HPV) contribute to prostate tumourigenicity and impact on the survival of patients with malignant PCa. Traditional therapies including chemotherapy and radiotherapy are unable to distinguish cancer cells from normal cells, which are a significant drawback and leads to toxicities for PCa patients undergoing treatment. So far, few other options are available for treating patients with advanced PCa. For PCa treatment, oncolytic virotherapy appears to be much more attractive, which uses live viruses to selectively kill cancer cells. Oncolytic viruses can be genetically engineered to induce cancer cell lysis through virus replication and expression of cytotoxic proteins. Conclusion: Virotherapy is being developed to be a novel therapy for cancers, which uses oncotropic and oncolytic viruses with their abilities to find and destroy malignant cells in the body. As oncolytic viruses are a relatively new class of anti-cancer immunotherapy agents, several important barriers still exist on the road to the use of oncolytic viruses for PCa therapy.Export Options
About this article
Cite this article as:
Virus, Oncolytic Virus and Human Prostate Cancer, Current Cancer Drug Targets 2017; 17 (6) . https://dx.doi.org/10.2174/1568009616666161216095308
DOI https://dx.doi.org/10.2174/1568009616666161216095308 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Related Books
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fluorescent Probes for the Detection of Hydrogen Peroxide in Biological Systems
Current Organic Chemistry Effect of PI3K/AKT/mTOR Signaling Pathway on Regulating and Controlling the Anti-Invasion and Metastasis of Hepatoma Cells by Bufalin
Recent Patents on Anti-Cancer Drug Discovery Importance of Male Fertility Control in Family Planning
Endocrine, Metabolic & Immune Disorders - Drug Targets Chronic Inflammation and Colorectal Cancer: The Role of Vascular Endothelial Growth Factor
Current Pharmaceutical Design Current Status and Future of Target-Based Therapeutics
Current Cancer Drug Targets Subject Index to Volume 9
Current Pharmaceutical Design Kinetic Models for Measuring P-glycoprotein Function at the Blood-Brain Barrier with Positron Emission Tomography
Current Pharmaceutical Design Medical Evaluation of Human MicroRNAs Needs to Address Recent Sequences and GC Content
Current Regenerative Medicine (Discontinued) The Role of Glycogen Synthase Kinase-3β in Normal Haematopoiesis, Angiogenesis and Leukaemia
Current Medicinal Chemistry Molecular and Genetic Bases of Pancreatic Cancer
Current Drug Targets Emerging Roles of microRNAs in the Molecular Responses to Hypoxia
Current Pharmaceutical Design 2-Deoxy-D-Ribose, a Downstream Mediator of Thymidine Phosphorylase, Regulates Tumor Angiogenesis and Progression
Anti-Cancer Agents in Medicinal Chemistry 3D-QSAR (CoMFA, CoMSIA) and Molecular Docking Studies on Histone Deacetylase 1 Selective Inhibitors
Recent Patents on Anti-Cancer Drug Discovery Microarray Technology as a Universal Tool for High-Throughput Analysis of Biological Systems
Combinatorial Chemistry & High Throughput Screening Current Advances in Retroviral Gene Therapy
Current Gene Therapy Inhibitors of 11β-Hydroxylase (CYP11B1) for Treating Diseases Related to Excess Cortisol
Current Medicinal Chemistry Vascular Disrupting Agents (VDA) in Oncology: Advancing Towards New Therapeutic Paradigms in the Clinic
Current Drug Targets Regulatory T Cells and Skin Tumors
Recent Patents on Inflammation & Allergy Drug Discovery Breath Analysis: The Approach Towards Clinical Applications
Mini-Reviews in Medicinal Chemistry Synthesis and Evaluation of A New Series of Thiazole Derivatives as Potential Antitumor Agents and MMP Inhibitors
Anti-Cancer Agents in Medicinal Chemistry